Table 2.
Clinical characteristics of patients in 233 episodes studied for possible decompensation
| No HF diagnosis, N = 57 | HF diagnosis, N = 176 | P value | |
|---|---|---|---|
| CDSS score | 0.68 ± 0.51 | 2.15 ± 0.97 | 0.001 |
| NYHA class III–IV, n (%) | 24 (42.1) | 129 (73.3) | <0.001 |
| Systolic BP (mmHg) | 121.7 ± 19.1 | 122 ± 20 | 0.92 |
| Heart rate (bpm) | 70 ± 12.6 | 77.0 ± 16.32 | 0.004 |
| Urea (mg/dL) | 55 (43.5–80) | 77 (55–122) | <0.001 |
| eGFR (mL/min/1.73 m2) | 59 ± 27.9 | 44.2 ± 22.4 | <0.001 |
| Haemoglobin (g/dL) | 12.9 ± 2.1 | 11.7 ± 1.9 | <0.001 |
| Na (mEq/L) | 137.6 ± 3.1 | 137.8 ± 3.3 | 0.69 |
| K (mEq/L) | 4.4 ± 0.5 | 4.2 ± 0.5 | 0.04 |
| NT‐proBNP (ng/L) a | 3145 ± 6425 | 8388 ± 8775 | <0.001 |
| sST2 (ng/mL) b | 46 ± 41.4 | 86.7 ± 53.9 | <0.001 |
| CA125 (U/mL) c | 15 (10–21.5) | 38 (18–38) | <0.001 |
| Clinical findings | |||
| Crackles | 1 (1.8) | 62 (35.2%) | <0.001 |
| Jugular venous distention | 4 (7.0) | 70 (39.8%) | <0.001 |
| Orthopnoea | 1 (1.8) | 49 (27.8%) | <0.001 |
| Paroxysmal nocturnal dyspnoea | 1 (1.8) | 28 (15.9%) | 0.003 |
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CA125, cancer antigen 125; CDSS, HF clinical disease severity score; eGFR, estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration equation); LUS, lung ultrasound; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; NYHA, New York Heart Association; sST2, soluble Interleukin‐1 receptor‐like 1.
Data in mean ± SD, median (Q1–Q3), or n (%).
a
N = 225.
b
N = 171.
c
N = 159.